CS Paper Radar

Probabilistic Steering of Generative Priors for Lab-in-the-Loop Antibody Optimization

Anisha Parsan, Sebastian Ober, Calvin McCarter, Nick Bhattacharya, Hunter Elliott

cs.LG ·submitted 2026-11-02 19:15 UTC · v1
top venue

Abstract

Therapeutic antibody development is often framed as comprising two discrete stages: initial discovery of novel binders followed by iterative optimization to refine these hits into therapeutic-grade molecules. Models and methods often reflect these stages, with generative structure models applied to discovery and probabilistic black-box optimization methods applied to refinement. Here we propose to unify these stages by smoothly transitioning a generative discovery model into iterative optimization, allowing the handoff between the structure-based prior and supervision from wet lab data to be guided by the posterior uncertainty of a probabilistic surrogate. We show that this yields improvements in optimization efficiency in the low-N regime, as well as improved diversity amongst the optimized molecules.

Comment
Accepted to NeurIPS `26 GEM and NeurIPS `26 AI4DD

Closest papers

Nearest neighbours by meaning across the whole index.

Multi-Objective Amortized CDRH3 Sequence Sampling Diversifies Promising Antibody Candidates

cs.CE ·2026-10-12 ·Joseph D. Viviano, Almer van der Sloot, Quentin Fournier, Robert M. Vernon, Christopher James Langmead +1 more
similarity 0.68
Abstract · 21 Figures, 14 Tables, Under review

Antibody therapeutics have transformed treatment across diverse therapeutic areas and have become central to modern medicine. While recent machine learning approaches aim to accelerate antibody discovery through structure-based design and target-affinity optimization, successful candidates must also satisfy broad developability constraints, including structural compatibility, low immunogenicity, and favorable biophysical properties, while remaining sufficiently diverse to provide sufficient coverage of design space to mitigate later-stage development failures. We introduce a preference-conditioned multi-objective generative flow network (GFN) fine-tuning pipeline for fixed-framework CDRH3 loop redesign that fine-tunes a biological sequence model against many inexpensive proxies covering backbone compatibility, sequence likelihood, immunogenicity risk, novelty, and developability liabilities. It combines up to fourteen predictive rewards in a single policy trained to sample CDRH3 loops across 623 SAbDab antibody structures, leveraging a reward reduction strategy to preserve Pareto dominance under this learned map. We also introduce a novel autoregressive span-in-filling variant of AMPLIFY-350M that serves both as a scaffold-conditioned CDRH3 generation prior and as a direct conditional likelihood scorer. We evaluated reward scores, diversity, and design quality on loops sampled on 45 held-out antibody complexes to assess structural consistency, confidence, aggregation propensity, stability, and antigen binding. Compared with the inverse-folding methods ProteinMPNN and ESM-IF, our approach produces roughly 10x more distinct acceptable candidates per design at 50% sequence identity, while holding 10% of the 14-objective Pareto front pooled across methods, trading per-sample quality for greater exploration of novel possible structures.

0.33

Large Discovery Models: Empirically-grounded Model-Based Open-Ended Search

cs.LG ·2026-08-16 ·Zhongwei Yu, Yan Song, Xue Yan, Anjie Liu, Xingyu Lu +7 more
similarity 0.65
Abstract

Scientific discovery often involves optimising expensive-to-evaluate objectives over vast, structured, and open-ended hypothesis spaces, such as molecules, protein sequences, and computer programs. Generative models such as large language models (LLMs) provide expressive priors over such spaces, but their likelihoods and self-assessments are unreliable proxies for the objectives and calibrated epistemic uncertainty, especially for novel candidates outside the observed data distribution. We introduce the Large Discovery Model (LDM), an empirically grounded recurrent architecture that couples a generative model with a Bayesian non-parametric reward surrogate model. The generative model proposes and refines candidate designs, while the surrogate predicts their performance and quantifies uncertainty, yielding an uncertainty-aware value that guides candidate generation, refinement, and selection. The discovery memory and the surrogate model are continually updated as each new experimental observation arrives. We evaluate LDM on three scenarios spanning different design modalities and objectives, including neural-network training, antibody design, and molecular optimisation. Compared to LLM-only reflection or traditional statistical search across these domains, LDM achieves a $2.4\times$ greater reduction in validation BPB, an $18.2\%$ relative decrease in binding energy, and more than $60\%$ relative gains in molecular multi-objective performance. These results suggests that LDM could serve as a general-purpose discovery engine for effective search over open-ended hypothesis spaces.

0.38

On the Selectivity of Generative Models in Structure-Based Drug Design

cs.LG cs.AI ·2026-10-16 ·Ella Miray Rajaonson, Jungyoon Lee, William Chau, Alan Aspuru-Guzik, Benjamin Sanchez-Lengeling +3 more
top venuebenchmarkcode/data similarity 0.65
Abstract · Accepted as a Presentation at the Neural Information Processing Systems 2026

Designing small-molecule drugs that selectively bind to a target protein while avoiding unintended interactions with other proteins is essential for reducing side effects that contribute substantially to clinical attrition. Although structure-based drug design (SBDD) has advanced rapidly with deep learning, most generative models still optimize binding to a single target and disregard selectivity due to limited training data and unknown off-target interactions. Motivated by this gap, we introduce SELECTBENCH, a comprehensive benchmark assessing the selectivity of generative SBDD models. SELECTBENCH provides three curated evaluation tasks reflecting different real-world drug discovery scenarios: literature-based case studies, safety screening panels used in pharmaceutical development, and large-scale structure-based evaluation sets. We further introduce a suite of metrics to quantify selectivity and conduct a systematic evaluation of nine representative SBDD models, including methods explicitly trained for selectivity and widely-used inference-time guidance techniques. Our results show that even selectivity-trained models achieve only modest off-target discrimination and inference-time guidance provides limited gains, underscoring the need for method improvement. SELECTBENCH provides both a characterization of where current generative SBDD stands on selectivity and an open, extensible platform to accelerate progress. The benchmark is available at https://github.com/lovetaro/selectbench.

0.44

Ensemble-Conditioned Molecular Design

cs.LG cs.NE ·2026-09-14 ·Ross Irwin, Alessandro Tibo, Jon Paul Janet, Simon Olsson
code/data similarity 0.63
Abstract · Code available at: https://github.com/rssrwn/ensemble-cond-design datasets and checkpoints available at: https://zenodo.org/records/22485204

Molecular design is typically approached as a problem of finding molecules which can adopt a single bioactive conformation. In reality, molecules occupy a distribution over conformations, and many of the properties which determine whether a candidate is viable depend on that distribution rather than on any single conformer. We reframe molecular design as an optimisation of both the modes and properties of molecules' conformational ensembles, where modes can be represented as shapes, pharmacophore profiles or protein pockets, and properties are aggregate scalars computed over the whole distribution. To realise this we introduce ensemble-conditioned guidance, a framework which conditions 3D molecular generative models on both axes simultaneously. Mode conditions are composed adaptively at inference by combining the vector fields produced under each condition. Conditions may be targeted or avoided, mixed across modalities and combined in arbitrary numbers, allowing a wide range of design tasks to be expressed with a single trained model. We introduce adaptive symmetry learning to allow conditions from different reference frames to be composed, and extend our generative framework to enable flexible-size generation. We evaluate on new benchmarks for multi-mode conditioning and ensemble property optimisation, and apply the framework to two practical drug discovery tasks, dual-target binder design and active-state-selective agonist design, where in both cases conditioning on the additional state improves the desired outcome over single-state conditioning.

0.40

Closed-Loop Molecular Inverse Design with Semantic LLM Surrogates

cs.CL ·2026-08-24 ·Yaoyao Xu, Xinjian Zhao, Xiaozhuang Song, Lei Bai, Tianshu Yu
similarity 0.63
Abstract · 24 pages

Practical molecular inverse design is rarely a one-shot generation problem; it often involves enriching a pool of molecules that match a desired property profile under a limited oracle budget. Bayesian optimization (BO) offers a natural framework for this setting, with standard Gaussian-process (GP) surrogates operating in continuous embedding spaces. We propose LoopMol, a closed-loop framework whose large language model (LLM) surrogate reasons directly over task instructions, SMILES-level optimization histories, and oracle feedback. At each iteration, the surrogate selects informative reference molecules under an exploration--exploitation principle, optionally with a concise guidance sentence. These outputs condition the next generation round and yield an inspectable optimization trace. Experiments on six drug and material tasks across three Llamole backbones show that the LLM-based variant improves over one-shot generation and is competitive with or stronger than GP-based BO. They also reveal a domain-dependent interface: reference-only conditioning performs better on binary drug tasks, while adding a concise guidance sentence generally benefits continuous material tasks.

0.34

Expanding the Decision Space of Pretrained Models through Structured Re-Decoding

cs.AI q-bio.BM ·2026-11-11 ·Tinglan Wang, Qun Su, Shihang Wang, Chi Wang, Lin Wang +9 more
similarity 0.61
Abstract · 29 pages, 2 figures

Native decoders limit how pretrained models combine local predictions under new structural constraints. We introduce Structured Re-Decoding (SRD), a training-free framework that constructs local candidates from model scores, samples, or external specifications, jointly optimizes their selection, and verifies reconstructed outputs. We show that candidate recombination expands feasible support and can improve attainable reward under a fixed KL divergence budget. Across molecular generation, protein design, RNA structure prediction, and antibody modeling, SRD enables improved structured inference, including verified molecules absent from the original sample pool. External chemical templates further extend SRD to noncanonical amino acids, peptide cyclization, and grammar-guided molecular construction. Preliminary experiments on a physical coherent Ising machine demonstrate the feasibility of hardware-based optimization, suggesting broader opportunities for quantum and quantum-inspired approaches to structured inference and combinatorial optimization across scientific domains.

0.24

Acquisition Function-Guided Generation for Bayesian Optimization over Discrete Spaces

cs.LG ·2026-10-16 ·Tommaso Ancilli, Thomas Wedenig, Henry Moss, Robert Peharz
code/data similarity 0.61
Abstract

Bayesian optimization (BO) over discrete spaces is challenging due to missing gradients and the sparsity of valid solutions. Latent-space BO sidesteps both issues by fitting a surrogate in the latent space of a generative model, which however substantially complicates the direct incorporation of domain knowledge that is naturally expressed in the original discrete space. In this work, we instead combine a pretrained generative model with a surrogate defined directly in data space, where inductive biases such as domain-specific kernels can be readily incorporated. Rather than maximizing the acquisition function over the discrete design space, our method samples candidates from the generative model under a distribution tilted by the acquisition function. To recover useful gradients for sampling, we embed this tilted distribution into a diffusion bridge that yields a smooth, posterior-averaged acquisition function. This leads to \emph{acquisition function guided generation} (AFGG), which we instantiate with a categorical diffusion model and an autoregressive normalizing flow. Across a broad suite of molecular benchmarks, the diffusion model variant performs on par with leading BO methods, while the flow model variant outperforms state-of-the-art methods in most cases and remains highly competitive otherwise. Our implementation is available at https://anonymous.4open.science/r/afgg.

0.24

Entropy-Guided Reverse-Causal AI to Identify Upstream Bottleneck Genes for Alzheimer's Drug Discovery

cs.CE ·2026-10-06 ·Victor O. K. Li, Jacqueline C. K. Lam, Yang Han, Lawrence Y. L. Cheung
similarity 0.61
Abstract

Identifying upstream regulators that connect several disease processes to therapeutic interventions is a central objective in Alzheimer's disease drug discovery. We propose an entropy-guided reverse-causal framework that makes candidate bottleneck genes the organizing link between disease mechanisms, pathways, molecular targets and drugs. The methodology integrates five stages: an Alzheimer's-specific knowledge graph with language-model assistance and expert review; reverse tracing from drugs to candidate genes; entropy-guided prioritization; forward propagation to drugs and complementary combinations; and staged validation with evidence feedback. The novelty lies in integrating upstream bottleneck identification, entropy-guided prioritization and iterative therapeutic selection within a dynamic, bidirectional discovery architecture. We demonstrate its molecular tracing and gene-prioritization components in a computational feasibility study using DeepDrug2 and MSigDB pathway annotations. Tracing amlodipine, indapamide and atorvastatin through a network of 11,300 molecular and drug nodes identifies 46 routes to nine genes. EGFR is the leading candidate, supported by 26 routes from all three drugs; MME and MAF rank next. These results show how pharmacological starting points can identify shared candidate genes with defined molecular connections. The framework's scientific significance lies in connecting convergent disease mechanisms to systematic intervention selection, with preservation of cognition and independence as the translational objective.

0.10